Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.37 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL456749 | 0.79 | HPGD (0.57) | — | |
| SCHEMBL31281981 | 0.78 | KMT2A (0.44) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL11711890 | 0.77 | KMT2A (0.67) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL31282172 | 0.76 | KMT2A (0.49) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL30423828 | 0.76 | GRIA1 (0.60) | KMT2ALMNAGRIA1GRIA2GRIA4 | |
| SCHEMBL770144 | 0.76 | KMT2A (0.60) | KMT2AMAPTKDM4EALDH1A1POLB | |
| SCHEMBL692624 | 0.76 | LMNA (0.61) | KMT2AKDM4ELMNAGRIA1GRIA2 | |
| SCHEMBL2153060 | 0.76 | GRIA1 (0.60) | KMT2AALDH1A1GRIA1GRIA2GRIA4 | |
| Ethylene Glycol SCHEMBL9298238 | 0.75 | HPGD (0.53) | — | |
| SCHEMBL22114480 | 0.73 | CYP1A2 (0.52) | KMT2AMAPTKDM4EALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | claimed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | claimed |
| US-12146139-B2 | Oligonucleotide interference treatments of prostate cancer | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2024-11-19 | — | — | US | claimed |
| WO-2023196944-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4058152-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220275374-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2022-09-01 | — | — | US | claimed |
| WO-2021097437-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2021-05-20 | — | — | WO | claimed |
| US-9333218-B2 | MicroRNA compositions and methods related thereto | EMORY UNIVERSITY (US) | 2016-05-10 | — | — | US | claimed |
| WO-1998042723-A9 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF NEUROPSYCHIATRIC DISORDERS | — | 1999-03-04 | — | — | WO | claimed |
| US-5486603-A | Oligonucleotide having enhanced binding affinity | GILEAD SCIENCES, INC. (US) | 1996-01-23 | — | — | US | claimed |
| US-20250277231-A1 | METHOD FOR GENERATING T-CELLS COMPATIBLE FOR ALLOGENIC TRANSPLANTATION | CELLECTIS (FR) | 2025-09-04 | — | — | US | disclosed |
| US-20250257360-A1 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | UNIV OKLAHOMA (US) | 2025-08-14 | — | — | US | disclosed |
| US-12252699-B2 | Method for generating t-cells compatible for allogenic transplantation | CELLECTIS (FR) | 2025-03-18 | — | — | US | disclosed |
| US-20250049815-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | BUCK INST RES AGING (US) | 2025-02-13 | — | — | US | disclosed |
| EP-4504945-A2 | OLIGONUCLEOTIDE INTERFERENCE TREATMENTS OF PROSTATE CANCER | The Board of Regents of the University of Oklahoma (US) | 2025-02-12 | — | — | EP | disclosed |
| WO-1997001571-A1 | NUCLEOTIDE AND PROTEIN SEQUENCES OF VERTEBRATE DELTA GENES AND METHODS BASED THEREON | IMPERIAL CANCER RESEARCH TECHNOLOGY, LTD. (GB) | 1997-01-16 | — | — | WO | disclosed |
| WO-1996027603-A9 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS | — | 1996-11-21 | — | — | WO | disclosed |
| EP-0537299-A1 | OLIGONUCLEOTIDE-TRANSPORT AGENT DISULFIDE CONJUGATES | GILEAD SCIENCES, INC. (US) | 1993-04-21 | — | — | EP | disclosed |
| EP-0537299-A4 | OLIGONUCLEOTIDE-TRANSPORT AGENT DISULFIDE CONJUGATES. | GILEAD SCIENCES INC (US) | 1993-02-05 | — | — | EP | disclosed |
| WO-1991014696-A1 | OLIGONUCLEOTIDE-TRANSPORT AGENT DISULFIDE CONJUGATES | GILEAD SCIENCES, INC. (US) | 1991-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049815-A1 | 25-HYDROXYCHOLESTEROL (25HC), CRYAB AGGREGATION INHIBITOR TO AMELIORIATE VASCULAR STIFFNESS | CRYAB, CRYAA, CRYZ | HDAC6 2404/4885KMT2A 2673/4885MAPT 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.